Trial Profile
Extension Study for Study ALT-103-201: One-year Follow-up for the 1×10(11th) vp NasoVAX Group
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Apr 2019
Price :
$35
*
At a glance
- Drugs ADhVN120304.H5 (Primary)
- Indications Influenza A virus infections
- Focus Pharmacodynamics
- Sponsors Altimmune
- 11 Apr 2019 According to an Altimmune media release, data from this trial will be presented at the World Vaccine Congress being held in Washington D.C. on April 14-17, 2019. The presentation will take place on April 16, 2019 at the Renaissance Washington, DC Downtown Hotel
- 19 Mar 2019 Results presented in an Altimmune media release.
- 04 Mar 2019 Status changed from recruiting to completed.